Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christoph Correll

Psychiatry Glen Oaks, NY Medical Doctor

NPI 1053475954 CMS profile 592394

The Zucker Hillside Hospital Dept Of Psych, 75 59 263Rd Street, Glen Oaks, NY 11004

Open in the dashboard

General payments

$1,548,946

740 records reported · program years 2019–2025

Research payments

$8,463

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$712,692 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Christoph Correll of Glen Oaks, NY is reported in the CMS Open Payments database as having received $1,548,946 across 740 general payments and $8,463 in research payments paid to them. Separately, studies naming them as principal investigator received $712,692 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $274,222 132
2025 Research $465 1
2024 General $206,287 163
2023 General $258,536 105
2022 General $216,580 103
2021 General $253,883 66
2021 Research $4,998 1
2020 General $99,292 48
2019 General $240,146 123
2019 Research $3,000 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christoph Correll
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Christoph Correll were reported at $274,222. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Christoph Correll Psychiatry median Middle half National median
2019 $240,146 $184 $59–$605 $163
2020 $99,292 $119 $36–$372 $114
2021 $253,883 $143 $43–$576 $132
2022 $216,580 $153 $50–$590 $149
2023 $258,536 $170 $56–$651 $160
2024 $206,287 $179 $57–$673 $164
2025 $274,222 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. H. Lundbeck A S $281,947 115 payments
  2. Teva Pharmaceuticals USA, Inc. $233,846 77 payments
  3. Alkermes, Inc. $155,445 78 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $127,557 72 payments
  5. Mylan Inc. $102,652 37 payments
  6. Sumitomo Dainippon Pharma Co., Ltd. $63,559 49 payments
  7. Seqirus USA Inc $63,467 17 payments
  8. Sunovion Pharmaceuticals Inc. $60,810 18 payments
  9. Otsuka Pharmaceutical Co., Ltd. $51,052 52 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $50,231 15 payments
  11. Other $358,379 210 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $799,525 206 payments
  2. Honoraria $300,329 82 payments
  3. Travel and Lodging $278,581 222 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $152,695 50 payments
  5. Food and Beverage $15,379 178 payments
  6. Education $2,436 2 payments
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $171,276 76 payments
  2. REXULTI $84,280 55 payments
  3. LYBALVI Cns $65,430 24 payments
  4. LYBALVI Cns $57,390 20 payments
  5. LYBALVI Cns $57,390 20 payments
  6. LYBALVI Cns $57,390 20 payments
  7. LATUDA $50,123 41 payments
  8. UZEDY $46,725 16 payments
  9. ARISTADA Cns $44,679 18 payments
  10. ARISTADA Cns $44,679 18 payments
  11. Other $484,706 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $4,998 1 payment
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,000 2 payments
  3. Novo Nordisk AS $465 1 payment

Records

744 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record